TEL AVIV, Feb 18 (Reuters) - Teva Pharmaceutical Industries (TEVA.O), the world’s biggest generic drug maker, has decided to exercise an option to invest $10.5 million in Andromeda Biotech, which is developing a treatment for juvenile diabetes.
TEL AVIV, Feb 18 (Reuters) - Teva Pharmaceutical Industries (TEVA.O), the world’s biggest generic drug maker, has decided to exercise an option to invest $10.5 million in Andromeda Biotech, which is developing a treatment for juvenile diabetes.
